Novel tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous administration by Fu, J.Y. et al.
Strathprints Institutional Repository
Fu, J.Y. and Zhang, Wei and Blatchford, David and Tetley, Laurence and Mcconnell, Gail and Dufès,
Christine (2011) Novel tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous
administration. Journal of Controlled Release, 154 (1). pp. 20-26. ISSN 0168-3659
Strathprints is designed to allow users to access the research output of the University of Strathclyde.
Copyright c© and Moral Rights for the papers on this site are retained by the individual authors
and/or other copyright owners. You may not engage in further distribution of the material for any
profitmaking activities or any commercial gain. You may freely distribute both the url (http://
strathprints.strath.ac.uk/) and the content of this paper for research or study, educational, or
not-for-profit purposes without prior permission or charge.
Any correspondence concerning this service should be sent to Strathprints administrator:
mailto:strathprints@strath.ac.uk
http://strathprints.strath.ac.uk/
Novel tocotrienol-entrapping vesicles can eradicate solid tumors
after intravenous administration
Ju Yen Fu a, Wei Zhang a, David R. Blatchford a, Laurence Tetley b, Gail McConnell a, Christine Dufès a,⁎
a Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, United Kingdom
b College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, United Kingdom
a b s t r a c ta r t i c l e i n f o
Article history:
Received 16 February 2011
Accepted 15 April 2011







The therapeutic potential of tocotrienol, a vitamin E extractwith anti-cancer properties, is hamperedby its failure
to specifically reach tumors after intravenous administration. In this work, we demonstrated that novel
transferrin-bearing, tocopheryl-based multilamellar vesicles entrapping tocotrienol significantly improved
tocotrienol uptake by cancer cells overexpressing transferrin receptors. This led to a dramatically improved
therapeutic efficacy in vitro, ranging from 17-fold to 72-fold improvement depending on the cell lines, compared
to the free drug.
In vivo, the intravenous administration of this novel tocotrienol formulation led to complete tumor eradication
for 40% of B16-F10 murine melanoma tumors and 20% of A431 human epidermoid carcinoma tumors. Animal
survival was improved by more than 20 days compared to controls, for the two tumor models tested. These
therapeutic effects, together with the lack of toxicity, potentially make transferrin-bearing vesicles entrapping
tocotrienol a highly promising therapeutic system as part as an anti-cancer therapeutic strategy.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
An extract of vitamin E, tocotrienol, has been the focus of anti-cancer
research for over two decades due to its tumor suppressive effects in
vitro. Todate, it has been found active onmanycancers in vitro, including
breast, pancreatic and prostate cancer cells [1–4]. In vivo, tocotrienol has
been used so far as a solution for oral administration or as a therapeutic
adjuvant. For example, oral supplementationof tocotrienol led to a delay
in tumor growth in B16 murine melanoma models [5]. The combined
treatment of γ-tocotrienol with celecoxib, a selective cyclooxygenase
inhibitor, recently resulted in synergistic anti-proliferative effects [6].
However, the therapeutic potential of tocotrienol is currently limited by
its failure to reach tumors at high concentrations after intravenous
administration without secondary effects on normal tissues.
In order to overcome this problem,we propose to entrap tocotrienol
in novel transferrin-bearingmultilamellar vesicles. Transferrin receptor
is an attractive target for selective receptor-mediated drug delivery to
tumors because of its overexpression on cancer cells, and has been
widely used for tumor-targeted drug delivery [7,8]. We recently
prepared for the first time a transferrin-bearing, Solulan-based
unilamellar vesicular formulation of tocotrienol, and evaluated its
anti-cancer therapeutic potential in vitro aswell as in vivo[9]. The results
obtained were promising, as this therapeutic system led to tumor
regression after intravenous administration. Unfortunately, this thera-
peutic effect only lasted for the duration of the treatment. In this study,
we seek to improve and prolong the benefit by entrapping the lipophilic
drug tocotrienol in a multilamellar rather than unilamellar vesicle, with
the aim of improving drug loading within the lipidic membranes and
therefore enhance the therapeutic efficacy of this system.
The objectives of this study are therefore to prepare and characterize
transferrin-bearingmultilamellar vesicles entrapping tocotrienol and to
evaluate their therapeutic efficacy in vitro and in vivo.
2. Materials and methods
2.1. Cell lines and reagents
Tocotrienol Rich Fraction of palm oil (TRF), a mixture of 17.6% α-
tocotrienol, 23.1%γ-tocotrienol, 15.1% δ-tocotrienol, 15.3%α-tocopherol,
and other tocotrienol-related compounds, was kindly donated by Dr.
Abdul Gapor from the Malaysian Palm Oil Board (Kuala Lumpur,
Malaysia). D-α-tocopheryl polyethylene glycol 1000 succinate (vitamin
E TPGS) was purchased from Eastman Chemical Company (Kingsport,
TN). A431 human epidermoid carcinoma and T98G human glioblastoma
were obtained from the European Collection of Cell Cultures (Salisbury,
UK). Bioware® B16-F10-luc-G5 mouse melanoma that expresses the
firefly luciferase and D-luciferin came from Caliper Life Sciences
(Hopkinton, MA). Tissue culture media were purchased from Invitrogen
(Paisley, UK). All other chemicals came from Sigma (Poole, UK).
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2.2. Preparation and characterization of transferrin-bearing TPGS
vesicles entrapping TRF
Transferrin (Tf)-bearing TPGS vesicles entrapping TRF were pre-
pared by modification of a previously describedmethod [9]. The vesicle
composition consisted of Span 60, cholesterol, TPGS and dioleoylpho-
sphatidylethanolamine (DOPE) in a 1:1:0.22:0.05 molar ratio. Control
vesicles entrapping TRF were prepared by shaking a mixture of Span 60
(65 mg), cholesterol (58 mg) and DOPE (6 mg) in TRF solution (2 mL,
5 mg/mL in TPGS) for 1 h at 60 °C, followed by probe sonication
(Soniprep150, Fisher Scientific, UK) for 4 minwith the instrument set at
75% of its maximal capacity. Transferrin (24 mg) was linked to the
vesicles (2 mL) by cross-linking with dimethylsuberimidate (12 mg) as
previously described [9,10]. Free drug was removed by ultracentrifuga-
tion as described [10]. Vesicles were visualized by transmission electron
microscopy (TEM) on a LEO 912 energy filtering electronmicroscope as
described [9]. TRF loading of the vesicles was measured spectro-
fluorometrically (λex 295 nm, λem 325 nm) [11], using a Varian Cary
Eclipse spectrofluorometer (Agilent Technologies, Santa Clara, CA ) after
disruption of vesicles with isopropanol. The amount of transferrin
conjugated to vesicles was determined using the Lowry method as
reported previously [10]. Size and zeta potential of the vesicles were
respectively measured by photon correlation spectroscopy and laser
Doppler electrophoresis on a Zetasizer Nano-ZS (Malvern Instruments,
Malvern, UK).
2.3. In vitro biological characterization
2.3.1. Cell culture
A431, T98G and B16-F10-luc-G5 cell lines overexpressing Tf
receptors were grown as monolayers in DMEM (A431 and T98G cells)
or RPMI-1640 medium (B16-F10-luc-G5 cells) supplemented with 10%
(v/v) fetal bovine serum, 1% (v/v) L-glutamine and 0.5% (v/v) penicillin-
streptomycin. Cells were cultured at 37 °C in a humid atmosphere of 5%
CO2.
2.3.2. Cellular uptake of TRF entrapped in Tf-bearing vesicles
Imaging of the cellular uptake of TRF carried by Tf-bearing vesicles
was carried out using coherent anti-Stokes Raman scattering (CARS)
microscopy [12]. This novel form of microscopy accurately detects
molecules by their intrinsic vibrational signal, without the need of an
exogenous fluorescence label. A431, T98G and B16-F10 cells were
grown in 4-well chamber slides (104 cells/well) at 37 °C for 72 h. The
cells were then incubated for 24 h with TRF (20 μg/well), either
entrapped in Tf-vesicles, control vesicles or in solution. They were
then washed three times with PBS, fixed in methanol for 10 min and
rinsedwith distilledwater before being examined using a home-made
CARS microscope [12]. Briefly, a synchronously pumped optical
parametric oscillator (OPO) based laser system was developed to
provide pump and Stokes beams. The pump laser generated a 1 ps
76 MHz pulse train with over 1.2 W of output power. Combining the
signal output of the OPO (180 mW) with a fraction of the titanium–
sapphire laser (120 mW), a total Raman range from 1900 cm−1 to
approximately 5700 cm−1 was accessible. Tocotrienol was detected
at 2916 cm−1 according to the Raman spectra of TRF that correlate
with the Raman peak reported by Beattie et al.[13] for the detection of
vitamin E in cellular structures. TRF cellular uptake was also
quantified by measuring the intensity of CARS signals in cells for
each treatment. Measurements were obtained by quantifying the
intensity of a 10 μm×10 μm square area at the brightest position in
the cell in each CARS image (n=10).
2.3.3. In vitro anti-proliferative activity
The anti-proliferative activity of TRF entrapped in Tf-bearing
vesicles, control vesicles or in solution was assessed in A431, T98G
and B16-F10 cell lines. Cells (2×103 cells per well in 96-well plates
seeded 72 h prior treatment) were incubated for 72 h with TRF
formulations at final concentrations of 1×10−7 to 1×102μg/mL TRF.
Anti-proliferative activity was evaluated by measurement of the
growth inhibitory concentration for 50% of the cell population (IC50)
in a standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide (MTT) assay. Dose–response curves were fitted to percent-
age absorbance values to obtain IC50 values (three independent
experiments with n=5 for each concentration level).
2.4. In vivo study
2.4.1. Animals
Female immunodeficient BALB/c mice (initial mean weight 20 g)
were housed in groups of five at 19 °C to 23 °C with a 12-hour light–
dark cycle. They were fed a conventional diet (Rat and Mouse
Standard Expanded, B&K Universal, Grimston, United Kingdom) with
mains water ad libitum. Experimental work was carried out in
accordance with UK Home Office regulations and approved by the
local ethics committee.
2.4.2. In vivo tumoricidal activity
Mice (n=5) bearing well-established, vascularized subcutaneous
A431 or B16-F10-luc-G5 tumors (one tumor per flank, implanted one
week before the start of the treatment), were treated by intravenous
tail vein injection of TRF entrapped in Tf-bearing vesicles and control
vesicles, or free in solution (10 μg TRF per injection) once daily for
20 days. Animals were weighed daily and tumor volume was
determined by caliper measurements (volume=d3×π/6). Results
were expressed as relative tumor volume (rel. Voltx=Voltx/Volt0) and
responses classified analogous to Response Evaluation Criteria in Solid
Tumors (RECIST) [14]. Progressive disease is defined as an increase in
relative tumor volume higher than 1.2-fold, stable disease as a relative
volume between 0.7 and 1.2 of starting volume, partial response as
measurable tumor with a reduction of more than 30% (0–0.7) and
complete response as the absence of any tumor.
The tumoricidal activity of the treatments was also visualized by
bioluminescence imaging, using an IVIS Spectrum (Caliper Life
Sciences, Hopkinton, MA). Mice bearing subcutaneous B16-F10-luc-
G5 tumors were treated intravenously as described above for 10 days.
They were then intraperitoneally injected with the luciferase
substrate D-luciferin (150 mg/kg body weight) and anaesthetized
by isoflurane inhalation every other day (Days 1, 3, 5, 7, 9 and 11).
Light emission was measured 10 min after injection of the D-luciferin
solution, for a duration of 2 min, using Living Image® software. The
resulting pseudocolor images represent the spatial distribution of
photon counts within the tumor. Identical illumination settings were
used for acquiring all images.
2.5. Statistical analysis
Results were expressed as means±standard error of the mean
(S.E.M). Statistical significance was determined by one-way analysis
of variance (ANOVA) followed by the Bonferroni multiple comparison
post-test (GraphPad Prism software). Differences were considered as
significant when Pb0.05.
3. Results and discussion
3.1. Preparation and characterization of transferrin-bearing TPGS
vesicles entrapping TRF
Sphericalmultilamellar TPGS vesicles encapsulating TRF and bearing
transferrin (Tf-vesicles) were successfully prepared, as confirmed by
TEM (Fig. 1A). The drug content in the vesicles was determined to be
48.6±1.7% of the initial TRF (2.29±0.25 mg TRF per mL of vesicles),
indicating that a higher loading of the hydrophobic drug was achieved
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when increasing the number of lipid bilayers forming these vesicles. It
was significantly enhanced compared to our previous TRF unilamellar
vesicle formulation, which had a TRF loading of around 28% [9].
Transferrin was conjugated at the surface of the vesicles at a level
of 25.7±2.5% of the initial amount of transferrin added. Consequent-
ly, loaded Tf-bearing vesicles displayed a larger z-average mean
diameter than that of control vesicles, respectively 341 nm (polydis-
persity: 0.377) and 184 nm (polydispersity: 0.368) for Tf-bearing and
control vesicles. As these sizeswere nevertheless smaller than the cut-
off size for extravasation, of 400 nm for most tumors [15,16], the
targeted vesicle has the required properties to reach the receptor-
expressing tumor cells.
Tf- and control vesicles were shown to be negatively charged, with
zeta potentials of −50 mV and −48 mV respectively for Tf-bearing
and control vesicles. Similar reduction of zeta potential upon
transferrin grafting to delivery systems was observed in previous
studies by Kircheis et al.[17]. These net negative charges would reduce












































Fig. 1. Preparation and characterization of transferrin-bearing vesicles entrapping TRF. A) Transmission electron micrograph confirming the formation of multilamellar vesicles
entrapping TRF and bearing Tf (Bar: 100 nm). B) CARS quantification of the cellular uptake of TRF (20 μg/well) either entrapped in Tf-vesicles, control vesicles or free in solution, in
A431, B16-F10 and T98G cell lines (controls: plain vesicles without any TRF, untreated cells)(n=10)(*: Pb0.05). C) CARS and transmissionmicroscopy imaging of the cellular uptake
of TRF (20 μg/well) either entrapped in Tf-vesicles, control vesicles or free in solution, after incubation for 24 h in A431, B16-F10 and T98G cells (controls: plain vesicles, untreated
cells). All images were taken in the size of 512 pixels×512 pixels and were averaged over 5 frames with a frame capture rate of 1.68 s. The pump wavelength and the Stokes beam
wavelength were tuned to 752.1 nm and 963.4 nm, corresponding to a Raman shift of 2916 cm−1 where the drug was expected to give the strongest CARS signals (bar: 10 μm).
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Our results demonstrated that Tf-bearing TPGS vesicles have
suitable physicochemical properties for being an efficient delivery
system of tocotrienol.
3.2. Cellular uptake of TRF
The entrapment of TRF in Tf-bearing vesicles significantly
improved TRF uptake by the three cell lines compared to TRF solution
and control vesicles (Fig. 1B and C). TRF uptake after treatment with
Tf-bearing vesicles was at least 1.5-fold higher than that of control
vesicles for all the cell lines. It wasmore than twice higher than that of
free drug for B16-F10 cells, 3-fold higher for T98G cells and 3.5-fold
higher for A431 cells. This improvement was similar to that previously
observed in our quantification of TRF uptake by fluorimetry [9], thus
confirming the possible use of CARS for quantitative analysis.
In terms of intracellular distribution, while treatment with control
vesicles and free TRF resulted in a disseminated distribution of TRF in
the cytosol, cells treated with Tf-vesicles showed a much localized
nuclear and perinuclear accumulation of TRF. As opposed to the non-
specific uptake observed with control vesicles and free TRF, uptake
mechanism via the endocytotic pathway often leads to vesicular
accumulation in the perinuclear region, further supporting the fact
that TRF carried by the Tf-bearing vesicles was most probably
transported into the cells via an endocytosis-mediated pathway [18].
3.3. In vitro therapeutic efficacy
The in vitro therapeutic efficacy of TRF was significantly improved
when formulated in vesicles, ranging from 2-fold to 21-fold
improvement depending on the cell lines (Table 1, Supplementary
Fig. 1). The targeting of the vesicles with transferrin further improved
the TRF therapeutic efficacy by 72-fold for A431 cells, 21-fold for T98G
cells and 17-fold for B16-F10 cells compared to that of free drug, with
IC50 ranging from 0.89±0.11 to 4.09±0.65 μg/mL. Collectively, the
observed therapeutic efficacy correlated well with the enhanced
cellular accumulation of tocotrienol when entrapped in transferrin-
targeted vesicles. The highest tocotrienol uptake observed in A431
cells led to the highest therapeutic efficacy in the same cell line, with a
dramatically improved magnitude of intensity, as a 3.5-fold drug
uptake improvement led to a 72-fold increase in therapeutic efficacy.
This might be explained by the fact that Tf-bearing vesicles facilitated
the internalization of tocotrienol in a specific manner. Unlike sparse
diffusional accumulation observed with free tocotrienol, uptake of
transferrin-targeted tocotrienol via receptor-mediated endocytosis
resulted in a high accumulation of tocotrienol in the cell nucleus,
essential for its anti-proliferative activity.
Table 1
Cytotoxicity of TRF, either entrapped in Tf-vesicles, control vesicles or free in solution,
in A431, B16-F10 and T98G cells, expressed as IC50 values (n=15).
Cell lines IC50 (μg/mL) (mean±S.E.M.)
Tf-vesicles Control vesicles Free TRF
A431 0.89±0.11 3.07±0.79 64.72±2.47
B16F10 4.09±0.65 36.98±4.52 71.86±6.01
T98G 1.24±0.13 2.58±1.23 26.48±2.86
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Fig. 2. A) Tumor growth studies in a mouse A431 xenograft model after intravenous
administration of Tf-vesicles encapsulating TRF (10 μg/injection) (green). Controls:
control vesicles encapsulating TRF (orange), TRF solution (red), untreated tumors
(black) (n=10). B) Variations of the animal body weight throughout the treatment. C)
Overall tumor response to treatments at the end of the study (Day 30). D) Time to
disease progression. The Y axis gives the proportion of surviving animals over time.
Animals were removed from the study once their tumor reached 12 mm diameter.
(Color coding as in A).
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3.4. In vivo tumoricidal activity
TRF entrapped in Tf-bearing vesicles slowed growth overall in
A431 and B16-F10 tumors compared to the other treatments, where
tumor growth proceeded unchecked (Figs. 2 and 3). This effect
occurred within 24 h and was maintained for the whole duration of
the experiment. TRF entrapped in Tf-bearing vesicles led to complete
tumor suppression for some mice and long-term survival of 100% of
the animals. On the last day of the experiment, 40% of B16-F10 tumors
and 20% of A431 tumors treated with Tf-vesicles entrapping TRF had
completely disappeared, while another 10% of both tumors showed a
partial response (Figs. 2C and 3C). Treatment with control vesicles led
to tumor regression for 10% of B16-F10 tumors and tumor stabiliza-
tion for 10% of A431 tumors. By contrast, 100% of the tumors treated
with free TRF or left untreated were progressive for both tumor types.
The tumoricidal activity of TRF entrapped in Tf-vesicles was also
qualitatively confirmed by bioluminescence imaging (Fig. 4). After
treatment with TRF entrapped in Tf-vesicles, luciferase expression in
B16-F10-luc tumors decreased at Day 5. Only traces of cancer cells
were detected at Days 7 and 9, leading to a complete eradication of
tumors at Day 11. By contrast, all the other treatments led to tumor
growth.
This dramatically improved therapeutic effect resulted in an
extended survival of the mice treated with targeted vesicles by
23 days compared to untreated mice for both tumor types (Figs. 2D
and 3D). Treatmentwith control vesicles led to a very limited extension
of mice survival compared to untreated mice, by 4 days and 2 days
respectively for A431 and B16-F10 tumors, thus emphasizing the crucial
need of a targeted delivery system for the systemic delivery of
tocotrienol to tumors. Treatment with free TRF did not extend the
survival of the animals compared to untreated mice.
The treatments were well tolerated by the mice and no apparent
signs of toxicity or weight loss were observed (Figs. 2B and 3B).
This work corresponds to a major improvement of the therapeutic
efficacy of tocotrienol for the treatment of tumors. In our previous
studies with Solulan-based transferrin-bearing vesicles [8], we
demonstrated that TRF entrapped in Tf-bearing vesicles was able to
induce tumor regression for the duration of the treatment, followed
by a tumor re-growth slower than that of all other treatment groups.
By contrast, results obtained with Tf-bearing TPGS vesicles were
characterized by a larger individual variability of responses to
treatment, but the therapeutic effect observed in this case was
prolonged even after halting the treatment. Even better, 40% of B16-
F10 tumors and 20% of A431 tumors treated with Tf-vesicles
entrapping TRF had completely disappeared and did not regrow for
the duration of the experiment. To our knowledge, it is the first time
that the intravenous administration of a tocotrienol formulation was
able to eradicate tumors. Moreover, these results demonstrate that
tocotrienol has the ability to exert an anti-cancer effect on its own in
vivo, not only as a therapeutic adjuvant or as a tumor growth inhibitor
as previously described [4,5], provided it is targeted to the tumors.
The therapeutic improvement observed with tocotrienol entrapped
within Tf-bearing vesicles might result from various factors. First, the
entrapment of the lipophilic tocotrienol within the lipidic membrane of
the vesicles offers the opportunity to administer this drug intravenously
while shielding it from degradation and metabolism, thus ensuring
sufficient circulating tocotrienol available for reaching the tumors.
Besides, higher doses can be administered as a result of increased drug
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Fig. 3. A) Tumor growth studies in a mouse B16-F10 model after intravenous
administration of Tf-vesicles encapsulating TRF (10 μg/injection) (green). Controls:
control vesicles encapsulating TRF (orange), TRF solution (red), untreated tumors
(black) (n=10). B) Variations of the animal body weight throughout the treatment. C)
Overall tumor response to treatments at the end of the study (Day 30). D) Time to
disease progression. The Y axis gives the proportion of surviving animals over time.
Animals were removed from the study once their tumor reached 12 mm diameter.
(Color coding as in A).
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payload when encapsulated in delivery systems, subsequently improv-
ing the dosing regimen and therapeutic index. The increase of the
treatment duration (from 10 to 20 days) might also play a very
important role in the observed therapeutic improvement. In addition to
elevated tumor accumulation due to the enhanced permeability and
retention effect [19], active targeting based on the use of transferrin
provides a tumor-selective targeting strategy, leading to an increased
delivery of tocotrienol to the tumors.
In conclusion, we have demonstrated for the first time that a novel
tocotrienol formulation can lead to complete tumor suppression after
intravenous administration. The entrapment of tocotrienol within
novel transferrin-bearing TPGS-based multilamellar vesicles signifi-
cantly improved tocotrienol uptake when compared to the free drug.
The in vitro therapeutic efficacy of TRF was significantly improved
when formulated in Tf-bearing vesicles, ranging from 17-fold to 72-
fold improvement depending on the cell lines, compared to that of
free drug.
In vivo, TRF entrapped in Tf-bearing vesicles led to complete tumor
suppression for 40% of B16–F10 tumors and 20% of A431 tumors, with
long-term survival of the animals. By contrast, 100% of the tumors
treated with free TRF or left untreated were progressive for both
tumor types. These benefits, together with the lack of toxicity, make
transferrin-bearing vesicles entrapping tocotrienol a highly promising
therapeutic tool.
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